Edwards Lifesciences Corporation $EW Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 6.0% during the 2nd quarter, Holdings Channel reports. The fund owned 175,780 shares of the medical research company’s stock after selling 11,219 shares during the quarter. Kennedy Capital Management LLC’s holdings in Edwards Lifesciences were worth $13,748,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Quantbot Technologies LP acquired a new stake in shares of Edwards Lifesciences during the first quarter worth about $26,000. SouthState Corp purchased a new position in shares of Edwards Lifesciences during the 1st quarter worth $27,000. Rosenberg Matthew Hamilton purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth $28,000. Costello Asset Management INC purchased a new position in Edwards Lifesciences in the first quarter valued at about $29,000. Finally, NewSquare Capital LLC boosted its stake in shares of Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 134 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.29% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on EW shares. Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Wells Fargo & Company increased their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research report on Thursday, August 7th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Stifel Nicolaus upped their price objective on Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Trading Down 0.9%

Shares of EW stock opened at $83.99 on Thursday. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.40. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $48.74 billion, a P/E ratio of 36.20, a P/E/G ratio of 3.78 and a beta of 0.97. The stock has a 50-day simple moving average of $80.54 and a 200 day simple moving average of $78.63.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the previous year, the company posted $0.67 EPS. The business’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.